Top Pre Filled Injection Device Manufacturers 2014-2024

1,560
-1

Published on

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1247/Medical-Device-Leader-Series-Top-Pre-Filled-Injection-Device-Manufacturers-2014-2024

Published in: Business, Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,560
On Slideshare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
47
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Top Pre Filled Injection Device Manufacturers 2014-2024

  1. 1. Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2014-2024 ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
  2. 2. www.visiongain.com Contents 1.1 Overview of Findings 1.2 Structure of the Report 1.3 Research and Analysis Methods 2.1 What are Pre-Filled Injection Devices? 2.2 Classification of Top Pre-Filled Injection Device Manufacturers 2.2.1 Glass vs. Plastic Syringes 2.3 Pen Injectors and Auto-Injectors 2.4 Advantages and Disadvantages to Pre-Filled Injection Devices 2.5 The World Pre-Filled Injection Devices Market, 2013 2.6 Pre-Filled Injection Devices Forecast, 2014-2024 2.7 Demand is Greatest in Developed Countries 2.8 Market Drivers and Restraints 3.1 Becton, Dickinson & Co (BD) 3.1.1 BD Has a Broad Pre-Filled Syringe Product Range 3.1.2 BD’s Proprietary Product: BD Hypak 3.1.3 BD Neopak: BD’s Latest Innovation 3.1.4 BD Sterifill 3.1.5 BD Soluvia Microinjection System 3.1.6 Uniject is a Product for Emerging Markets 3.1.7 BD Physioject: BD’s Autoinjector 3. Leading Pre-Filled Syringe Manufacturers, 2014 2. The Pre-Filled Injection Devices Market, 2014-2024 1. Executive Summary
  3. 3. www.visiongain.com Contents 3.1.8 BD Vystra Disposable Pen is the Company’s Latest Pre-Filled Injection System 3.1.9 BD Markets Pen Injectors for Lyophilised Drugs 3.1.10 BD’s Proprietary Syringe Safety Systems 3.1.11 Outlook for BD Sales, 2010-2013 3.1.12 BD Revenues by Geographical Location, 2013 3.1.13 BD Medical’s Pharmaceutical Systems: Revenue Forecast 2014-2024 3.1.14 SWOT Analysis of BD’s Pre-Filled Syringes Market Potential, 2014-2024 3.2 Gerresheimer: A Leading Supplier of Glass and Plastics 3.2.1 Gerresheimer’s Pre-Filled Syringe Products, 2014 3.2.2 Ready-To-Fill (RTF) Syringes 3.2.3 Gerresheimer Licensed Polymer Syringes from Taisei Kako 3.2.4 Gerresheimer Began Manufacturing Pen Injectors in 2009 3.2.5 Strong Revenue Growth for Gerresheimer, 2012-2013 3.2.6 Outlook for Gerresheimer’s Pre-Filled Injection Devices Market, 2014-2024 3.2.7 SWOT Analysis of Gerresheimer’s Pre-Filled Injection Devices Market Potential, 2014- 2024 3.3 Schott: One of the World’s Leading Manufacturers of Glass Products 3.3.1 Schott Produces over 600 Product Lines 3.3.2 Glass Syringes: syriQ 3.3.3 TopPac Polymer Syringes 3.3.4 Schott’s Financial Performance, 2011-2013 3.3.5 SWOT Analysis of Schott’s Pre-Filled Syringes Market Potential, 2014-2024 3.4 Nipro Corporation: A Market Leader via its MGlas Acquisition 3.4.1 Outlook for Nipro’s Pre-Filled Injectables Market, 2014-2024 3.4.2 SWOT Analysis of Nipro’s Pre-Filled Injectables Market Potential, 2014-2024
  4. 4. www.visiongain.com Contents 3.5 The Stevanato Group Among the World Leaders 3.5.1 The Glass Division Includes Nuova Ompi 3.5.2 Nuova Ompi: A Pre-Filled Syringe Specialist 3.5.2.1 EZ-Fill Syringes 3.5.2.2 Extra High Quality (XQ) Syringes 3.5.2.3 Investment in New Mexican Facility 3.5.3 SWOT Analysis of Nuova Ompi’s Pre-Filled Syringes Market Potential, 2014-2024 3.6 Unilife Corporation 3.6.1 Pre-filled Syringes for Reconstitution 3.6.2 Autoinjectors: RITA and LISA 3.6.3 Novel Delivery Technologies 3.6.4 Unilife Settles Supply Agreements with Pharma Giants to Improve Market Presence 3.6.5 How Will Unilife Grow over the Forecast Period? 3.6.6 SWOT Analysis of Unilife’s Market Potential, 2014-2024 3.7 Pre-Filled Syringe Manufacturers Porter’s Five Forces Analysis, 2014-2024 3.7.1 Rivalry Among Competitors 3.7.2 Manufacturers Striving to Improve Safety Systems 3.7.3 Increasing Product Portfolio Diversity 3.7.4 Threat of New Entrants 3.7.5 Power of Suppliers 3.7.6 Power of Buyers 3.7.7 Threat of Substitutes 4.1 Aptar Stelmi: A Pharma Packaging Specialist 4. Leading Pre-Filled Syringe Component Manufacturers, 2014
  5. 5. www.visiongain.com Contents 4.1.1 Aptar Stelmi’s Pre-Filled Syringe Components, 2014 4.1.2 Rigid Needle Shields 4.1.3 Company Acquired Oval Medical to Include Autoinjectors 4.1.4 Financial Progress, 2014-2024 4.1.5 What Are the Strengths and Weaknesses of Aptar Stelmi in the Pre-Filled Syringes Market? 4.2 The Datwyler Group 4.2.1 Datwyler’s Pre-Filled Syringe Components, 2014 4.2.2 Omniflex Coating: Alternative to Silicone 4.2.3 Expansion of FirstLine Range 4.2.4 The Sealing Solutions Division 4.2.4.1 Demand from Vaccine and Insulin Manufacturers Driving Growth 4.2.5 Outlook of Datwyler’s Pharma Packaging Division, 2014-2024 4.2.6 SWOT Analysis of Datwyler’s Pre-Filled Syringe Business: Market Potential, 2014-2024 4.3 West Pharmaceutical Services 4.3.1 West’s Packaging Systems 4.3.2 West’s Delivery Systems 4.3.2.1 Daikyo CZ: The First Silicone-Free Polymer Syringe 4.3.2.2 SmartDose: A Novel Patch Injector 4.3.3 West Also Develops Autoinjectors and Self Injectors 4.3.4 MixJect: Addressing Lyophilised Drugs 4.3.5 West Pharmaceutical’s Financial Performance in 2013 4.3.6 Outlook for West’s Pre-Filled Syringes Market, 2014-2024 4.3.7 SWOT Analysis of West Pharmaceutical’s Pre-Filled Syringe Market Potential, 2014- 2024
  6. 6. www.visiongain.com Contents 4.4 Pre-Filled Syringe Component Manufacturers Porter’s Five Forces Analysis, 2014-2024 4.4.1 Rivalry Among Competitors 4.4.1.1 Emerging National Markets Will Become More Important 4.4.2 Threat of New Entrants 4.4.3 Power of Suppliers 4.4.4 Power of Buyers 4.4.5 Threat of Substitutes 5.1 Catalent: The World’s Leading CMO 5.1.1 High Pre-Filled Syringe Contract Manufacturing Capabilities 5.1.2 Outlook for Catalent’s Pre-Filled Syringes Services, 2014-2024 5.1.3 SWOT Analysis of Catalent’s Contract Pre-Filled Syringe Filling Potential, 2014-2024 5.2 Hospira One2One Offers Contract Manufacturing Services 5.2.1 Hospira’s Pre-Filled Syringes, 2014 5.2.2 Speciality Injectable Pharmaceuticals is the Largest Division 5.2.3 Outlook for Hospira’s Contract Manufacturing Services, 2014-2024 5.2.4 SWOT Analysis of Hospira One2One Market Potential, 2014-2024 5.3 Vetter Pharma 5.3.1 An Injectable Manufacturing Specialist 5.3.2 Vetter Expands in The US and Germany 5.3.3 SWOT Analysis of Vetter’s Contract Pre-Filled Syringe Filling Capacitates, 2014-2024 5.4 Baxter Has its Own CMO 5.4.1 BioPharma Solutions 5.4.2 SWOT Analysis of BioPharma Solution’s Services, 2014-2024 5. Leading Pre-Filled Syringe Contract Manufacturers, 2014
  7. 7. www.visiongain.com Contents 5.5 Laboratorios Farmacéuticos ROVI 5.5.1 ROVI’s Pre-Filled Syringe Capabilities, 2014 5.5.2 SWOT Analysis of ROVI’s Contract Manufacturing Potential, 2014-2024 5.6 Albany Molecular Research Inc (AMRI) 5.6.1 AMRI’s Financial Performance in 2013 5.6.2 SWOT Analysis of AMRI’s Contract Manufacturing Services, 2014-2024 5.7 Porter’s Five Forces Analysis of Pre-Filled Syringe Contract Manufacturers, 2014-2024 5.7.1 Rivalry Among Competitors 5.7.2 Threat of New Entrants 5.7.3 Power of Suppliers 5.7.4 Power of Buyers 5.7.5 Threat of Substitutes 6.1 Ypsomed: Diabetes Specialists for over 25 Years 6.1.1 Yposomed’s Long List of Pen Injectors & Autoinjectors, 2014 6.1.2 YpsoPen: A Reusable Insulin Pen 6.1.3 ServoPen 6.1.4 UnoPen Range 6.1.5 LyoTwist Injectors for Lyophilised Drugs 6.1.6 Ypsomed Markets Two Autoinjectors 6.1.7 VarioJect 6.1.8 Ypsomed Outlook, 2014-2024 6.1.9 What Are Ypsomed’s Strengths and Weaknesses? 6.2 Haselmeier: A Specialist in Self-Injection Devices 6. Leading Pen Injectors and Autoinjector Manufacturers, 2014
  8. 8. www.visiongain.com Contents 6.2.1 Axis Pen Systems 6.2.2 i-Pen: Haselmeier’s Lead Product 6.2.3 Penlet Used For the Administration of Enoxaparin 6.2.4 The SoftPen Platform 6.2.5 SWOT Analysis of Haselmeier’s Injectables Market Potential, 2014-2024 6.3 SHL Group 6.3.1 Divisions and Activities of that Company 6.3.1.1 A Broad Product Portfolio, 2014 6.3.1.2 Amber Autoinjector: SHL’s Later Innovation 6.3.1.3 Molly Autoinjector 6.3.1.4 DAI Series Most Successful 6.3.2 SHL Group Continues to Grow in Taiwan 6.3.3 SWOT Analysis of SHL Group’s Market Potential, 2014-2024 6.4 Owen Mumford 6.4.1 Autoinjector and Pen Injector Overview 6.4.2 The Autopen Series 6.4.3 Unifine Pentips for Improved Comfort 6.4.4 How Does Owen Mumford Compete? 6.4.5 SWOT Analysis of Owen Mumford’s Market Potential, 2014-2024 6.5 Porter’s Five Forces Analysis of the Pen Injector and Autoinjector Manufacturers, 2014-2024 6.5.1 Rivalry Among Competitors 6.5.2 Threat of New Entrants 6.5.3 Power of Suppliers 6.5.4 Power of Buyers 6.5.5 Threat of Substitutes
  9. 9. www.visiongain.com Contents 7.1 Interview with Mr Simon Williams, Business Development at Duoject Medical Systems, Quebec, Canada 7.1.1 The Current Pre-Filled Injectables Market 7.1.2 What Does Duoject Offer? 7.1.3 Pre-Filled Syringes Will Continue to Dominate the Market 7.2 Interview with a Respondent from a Leading Company Involved in the Pre-Filled Injection Devices Market 7.2.1 The Potential of the Pre-Filled Injections Market 7.2.2 Changing Demands 8.1 The Pre-Filled Injection Devices Market in 2013 8.2 Leading Pre-Filled Injection Device Manufacturers in 2014 8.3 The World Pre-Filled Injection Devices Market: Predictions to 2024 8.4 Outlook for the Pre-Filled Injection Device Manufacturers 2014-2024 8.4.1 Emerging Countries Will Play Pivotal Role 8.5 Future of the Pre-Filled Injection Device Manufacturers Market About Visiongain’s Bespoke Research Service Appendix A: About Visiongain Appendix B: Visiongain Report Evaluation Form Appendices 8. Conclusions 7. Research Interviews
  10. 10. www.visiongain.com Page 57 Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2014-2024 Table 3.11 Gerresheimer Pre-filled Injection Systems: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024 2013 2014 2015 2016 2017 2018 Revenues ($m) 346 363 389 424 466 517 AGR (%) 5 7 9 10 11 CAGR (%) 8.4 2019 2020 2021 2022 2023 2024 Revenues ($m) 564 615 664 710 760 813 AGR (%) 9 9 8 7 7 7 CAGR (%) 7.8 Figure 3.8 Gerresheimer Pre-filled Injection Systems: Revenue Forecast ($m), 2013- 2024 0 100 200 300 400 500 600 700 800 900 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Revenues($m) Year Source: visiongain 2014; CAGR values for year ranges 2013-2018 and 2018-2024 Source: visiongain 2014
  11. 11. www.visiongain.com Page 139 Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2014-2024 for drug administration. For patients, the more complicated process may reduce regimen compliance. Syringe manufacturers have overcome this problem through the development of dual- chamber pre-filled syringes, where the drug and diluent are reconstituted in the syringe prior to injection. At present, visiongain believes there are few companies offering lyophilisation and filling services for pre-filled syringes. Vetter is one of these companies and it also offers its own proprietary dual- chamber syringe systems. Vetter can lyophilise 24 million units annually at its sites in Germany, which is significant capacity compared with other contract manufacturers. For that reason, visiongain believes that the company will remain the market leader in lyophilisation and filling of dual-chamber syringes in the next 10 years. However, as demand for outsourced filling of biologics in lyophilised state increases, many other companies will enter this market. A number of smaller CMOs have already indicated that they intend to expand into this field, visiongain notes. Therefore, visiongain predicts the threat of new entrants to be moderate, eventually increasing over the forecast period. 5.7.3 Power of Suppliers The bargaining power of suppliers is moderate for contract manufacturers of pre-filled syringes. As many biopharmaceutical companies are looking to outsource their services to contract manufacturers. Of the six companies profiled in this chapter, visiongain expects Vetter, Hospira and Catalent to have high bargaining power. By offering a wide range of novel services across global facilities, means they are market leaders in the pre-filled syringes contract manufacturing market. Smaller contract manufacturing companies on the other hand, may have low bargaining power as they are competing with other companies. 5.7.4 Power of Buyers The overall bargaining power of buyers in pre-filled syringe contract manufacturers is moderate, although it has been increasing in recent years. There is a large range of buyers in the pharmaceutical and diagnostics markets which includes hospitals, specialty clinics, medical devices manufactures as well as payers such as healthcare insurance companies. Reimbursement agencies such as NICE are the main buyers, with high bargaining power to determine cost efficiencies of development. Furthermore, the increasing demand on comparative effectiveness research studies will give health insurers, and government healthcare institutions a significant bargaining power over companies as the information coming from such studies will reinforce cost- effectiveness based decisions.
  12. 12. www.visiongain.com Page 164 Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2014-2024 Emerging markets, in particular the BRIC nations, will become an important source of revenue for pen injector and autoinjector manufacturers in the coming 10 years, as a result of the rising incidence of chronic diseases, such as diabetes. Some leading manufacturers already have well- established alliances with biosimilar insulin manufacturers in emerging markets. Ypsomed, for example, is partnered with Tonghua Dongbao in China, Pharmstandard in Russia and Polfa Tarchomin in Poland. Figure 6.3 Porter’s Five Forces Analysis of Pen Injector and Auto-Injector Manufacturers, 2014-2024 Rivalry Among Competitors [High] Threat of New Entrants [High] Power of Buyers [High] Threat of Substitutes [Moderate] Power of Suppliers [Low] Source: visiongain 2014

×